Drug
Edp 305 Dose 1
Edp 305 Dose 1: highest development phase Phase 2, developed by Enanta Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Enanta Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| EDP-305 Dose 1 NCT03421431 | Phase 2 | Non-Alcoholic Steatohepatitis |
Latest
No recent events.
Follow Edp 305 Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.